Sanofi SNY announced that the FDA has accepted its regulatory filing seeking approval for its investigational BTK inhibitor ...
This Phase 2 trial aims to assess the safety, tolerability, and foralumab’s effect on microglial activation in patients with na-SPMS. Intranasal foralumab offers a novel approach to potentially ...
Sanofi SNY announced that the FDA has accepted its regulatory filing seeking approval for its investigational BTK inhibitor ...